Archive for August, 2014

(TAST) to Purchase 64 BURGER KING® Restaurants in Tennessee, Indiana and Illinois

Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (Nasdaq:TAST) today announced that on August 22, 2014 it signed definitive agreements to purchase 64 BURGER KING® restaurants from certain subsidiaries of Heartland Food LLC for a total cash purchase price of approximately $18.0 million excluding inventory. The restaurants to be acquired are located in or around the following markets: Nashville, TN (27 restaurants), Springfield, IL (11 restaurants), Terre Haute, IN (15 restaurants), Evansville, IN (7 restaurants), and other nearby markets (4 restaurants).

Daniel T. Accordino, the Company’s Chief Executive Officer said, “The consummation of this transaction will expand our footprint to a number of markets contiguous to our existing operations and is consistent with our stated strategy to enhance shareholder value through our expanding ownership within the BURGER KING® system. Since our stock offering earlier this year we have completed the acquisition of 29 BURGER KING® restaurants, and the expected closing of this transaction will bring our total 2014 acquisitions to almost 100 restaurants. We also continue to evaluate additional opportunities.”

The transaction is subject to certain closing conditions including satisfactory completion by the Company of due diligence and other customary closing conditions. In conjunction with the transaction, Burger King Corporation has also agreed to make a cash payment to Heartland at closing based on Carrols’ commitment to remodel 46 of the restaurants. Closing is expected to occur in late September or early October.

About the Company

Carrols Restaurant Group, Inc. is the largest BURGER KING® franchisee in the world with 583 restaurants as of August 22, 2014 and has operated BURGER KING® restaurants since 1976. For more information on Carrols, please visit the company’s website at www.carrols.com.

Forward-Looking Statements

Except for the historical information contained in this news release, the matters addressed are forward-looking statements. Forward-looking statements, written, oral or otherwise made, represent Carrols’ expectation or belief concerning future events. Without limiting the foregoing, these statements are often identified by the words “may”, “might”, “believes”, “thinks”, “anticipates”, “plans”, “expects”, “intends” or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such statements reflect management’s current views with respect to future events and are subject to risks and uncertainties, both known and unknown. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. Investors are referred to the full discussion of risks and uncertainties as included in Carrols’ filings with the Securities and Exchange Commission.

Friday, August 22nd, 2014 Uncategorized Comments Off on (TAST) to Purchase 64 BURGER KING® Restaurants in Tennessee, Indiana and Illinois

(ASTM) Ixmyelocel-T Shown To Reduce Incident Rates, Ischemic Dilated Cardiomyopathy

Results From Phase 2a IMPACT-DCM and Catheter-DCM Studies Published in Circulation Research

ANN ARBOR, Mich., Aug. 22, 2014  — Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that results from the company’s Phase 2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM) were published in the peer-reviewed journal Circulation Research. In an article entitled “Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy,” results showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM.

In two separate open-label studies, a total of 61 patients were randomized and 59 were treated or received standard of care. The combined results among ischemic DCM patients demonstrated that patients treated with ixmyelocel-T experienced fewer MACE events during follow up compared to control patients. Heart failure (HF) exacerbation was the most common MACE. Relative to the control patients, ischemic DCM patients treated with ixmyelocel-T also experienced an improvement in symptoms as measured by the New York Heart Association classification system, a six-minute walk test, and the Minnesota Living with Heart Failure Questionnaire. Similar benefits were not observed in the non-ischemic population.

“The publication of results from the two Phase 2a trials in a peer-reviewed journal is further validation that the available evidence supports continued development of ixmyelocel-T as a treatment for patients with ischemic dilated cardiomyopathy. We currently are enrolling a larger, Phase 2b trial and hope to replicate these very promising results. People living with ischemic DCM are often severely compromised and have very limited treatment options available, so these results are especially encouraging,” said Dave Recker, M.D., Aastrom’s chief medical officer.

Ixmyelocel-T is a patient-specific, expanded multicellular therapy manufactured from the patient’s own bone marrow using Aastrom’s proprietary, highly automated, fully closed cell-processing system. This process selectively expands the population of mesenchymal stromal cells and alternatively activated macrophages, which are responsible for production of anti-inflammatory and pro-angiogenic factors known to be important for repair of damaged tissue.

Based upon these results, we see great promise in the use of ixmyelocel-T to treat dilated cardiomyopathy and are working aggressively to advance this development program to the final stages of clinical research and regulatory review,” Dr. Recker added. “As recently announced, we are on pace to enroll 108 patients by year end in the Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T for the treatment of advanced heart failure due to DCM.”

About Aastrom Biosciences

Aastrom Biosciences is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit Aastrom’s website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663

This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our products and growth in revenues, intended product development, clinical activity timing, and objectives and expectations regarding the business opportunity described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “we believe,” “we intend,” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “potential,” “could,” “may,” or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements, the availability and allocation of resources among different potential uses, estimating the commercial potential of our products and product candidates and growth in revenues, market demand for our products, and our ability to supply or meet customer demand for our products. These and other significant factors are discussed in greater detail in Aastrom’s Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (“SEC”) on March 13, 2014, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management’s current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Media contact:
         David Salisbury
         Berry & Company
         dsalisbury@berrypr.com
         (212) 253-8881

         Investor contact:
         Chad Rubin
         The Trout Group
         crubin@troutgroup.com
         (646) 378-2947
Friday, August 22nd, 2014 Uncategorized Comments Off on (ASTM) Ixmyelocel-T Shown To Reduce Incident Rates, Ischemic Dilated Cardiomyopathy

(CCIH) to Participate in Morgan Stanley Flagship China Internet, E-Commerce Conference

BEIJING, Aug. 22, 2014  — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq:CCIH), the leading total solutions provider of Internet content and application delivery services in China, today announced that it will participate in Morgan Stanley Flagship China Internet & E-Commerce Conference on Monday, August 25, 2014, at the Four Seasons Hotel in Beijing, China. Management is scheduled to present at 12:30 pm local time on August 25, 2014.

Management will meet with institutional investors throughout the event. For additional information, please contact the institutional sales representative at Morgan Stanley.

About ChinaCache

ChinaCache International Holdings Ltd. (Nasdaq:CCIH) is the leading total solutions provider of Internet content and application delivery services in China. As a carrier-neutral service provider, ChinaCache’s network in China is interconnected with networks operated by all telecom carriers, major non-carriers and local Internet service providers. With more than a decade of experience in developing solutions tailored to China’s complex Internet infrastructure, ChinaCache is a partner of choice for businesses, government agencies and other enterprises to enhance the reliability and scalability of online services and applications and improve end-user experience. For more information on ChinaCache, please visit ir.chinacache.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the outlook for the third quarter of 2014 and quotations from management in this announcement, as well as ChinaCache’s strategic and operational plans, contain forward-looking statements. ChinaCache may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statements, including but not limited to the following: the Company’s goals and strategies, expansion plans, the expected growth of the content and application delivery services market, the Company’s expectations regarding keeping and strengthening its relationships with its customers, and the general economic and business conditions in the regions where the Company provides its solutions and services. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and ChinaCache undertakes no duty to update such information, except as required under applicable law.

CONTACT: For investor and media inquiries please contact:

         Mr. David She
         Investor Relations
         ChinaCache International Holdings
         Tel: +86 (10) 6408 5307
         Email: ir@chinacache.com

         Mr. Glenn Garmont or Mr. Don Markley
         The Piacente Group | Investor Relations
         Tel: +1 212-481 2050
         Email: chinacache@tpg-ir.com
Friday, August 22nd, 2014 Uncategorized Comments Off on (CCIH) to Participate in Morgan Stanley Flagship China Internet, E-Commerce Conference

(SPPR) Announces Sale of Stone Mountain Savannah Suites

NORFOLK, NE–(August 22, 2014) – Supertel Hospitality, Inc. (NASDAQ: SPPR), a real estate investment trust (REIT), today announced that it has sold the 140-room Savannah Suites in Stone Mountain, Georgia, on August 21, 2014 for $1.5 million. Supertel will use the proceeds from the sale to retire the mortgage on the property.

The company closed on the sale of the Savannah Suites in Jonesboro, Georgia, on July 15, 2014 for $1.4 million. “We are actively marketing our remaining five Savannah Suites hotels,” said Kelly Walters, Supertel’s President and Chief Executive Officer. “These economy extended stay properties have been consistent performers for Supertel, and the segment is enjoying strong fundamentals with a very positive long-term outlook, but our plan for the future is to build our core portfolio around premium branded, upper midscale and upscale, select-service brands.”

Year-to-date the company has sold eight non-core assets with combined gross proceeds of $13.1 million. The proceeds were used to reduce debt.

About Supertel Hospitality, Inc.

Supertel Hospitality, Inc. (NASDAQ: SPPR) is a self-administered real estate investment trust that specializes in the ownership of select-service hotels. The company currently owns 61 hotels comprising 5,319 rooms in 20 states. Supertel’s hotels are franchised by a number of the industry’s most well-regarded brand families, including Hilton, IHG, Choice and Wyndham. For more information or to make a hotel reservation, visit www.supertelinc.com.

Certain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance to differ from those projected in the forward-looking statement. These risks are discussed in the company’s filings with the Securities and Exchange Commission.

Contact:
Ms. Krista Arkfeld
Director of Corporate Communications
karkfeld@supertelinc.com

Friday, August 22nd, 2014 Uncategorized Comments Off on (SPPR) Announces Sale of Stone Mountain Savannah Suites

(EMITF) Announces Effectiveness of Reverse Share Split

Elbit Imaging Ltd. (“EI” or “Company“) (NASDAQ GSM: EMITF) announced today that the previously announced one-for-twenty reverse split of the Company’s ordinary shares became effective at 5:00 p.m. (New York time) on Thursday, August 21, 2014 and that the shares commenced trading on a reverse split-adjusted basis upon the open of trading on the NASDAQ Global Select Market on Friday, August 22, 2014. With respect to the Tel Aviv Stock Exchange, the shares will commence trading on a reverse split-adjusted basis upon the open of trading on Sunday, August 24, 2014.

As part of the reverse share split and pursuant to the approval of the Company’s shareholders, on August 21, 2014 the Company’s Memorandum and Articles of Association were amended to reduce the Company’s authorized share capital from 700,000,000 ordinary shares, no par value, to 35,000,000 ordinary shares, no par value.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers – Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India, primarily through its subsidiary Plaza Centers N.V. In certain circumstances and depending on market conditions, we operate and manage commercial and entertainment centers prior to their sale; (ii) Hotels – Hotel operation and management; (iii) Medical Industries – (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (iv) Residential Projects – Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India; (v) Fashion Apparel – Distribution and marketing of fashion apparel and accessories in Israel.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “would,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2013, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.

For Further Information:

Company Contact:
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
ron@elbitimaging.com

Friday, August 22nd, 2014 Uncategorized Comments Off on (EMITF) Announces Effectiveness of Reverse Share Split

(OGXI) Update on Phase 3 ENSPIRIT Trial Of Custirsen In Lung Cancer

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.

“While the results of the study remain blinded to OncoGenex and Teva, we are very pleased that ENSPIRIT has passed this important early interim futility analysis,” said Scott Cormack, President and CEO of OncoGenex. “We remain strong in our belief that targeting mechanisms of treatment resistance is a critical path forward in the fight against cancer and we continue to actively pursue this approach through the two ongoing Phase 3 trials of custirsen and the seven Phase 2 trials of apatorsen in four tumor types.”

The Phase 3 ENSPIRIT trial is an international, randomized, open-label trial designed to evaluate a survival benefit for custirsen in the treatment of advanced or metastatic non-small cell lung cancer in 1,100 patients who have progressed after initial chemotherapy treatment. Patients are randomized to receive custirsen plus docetaxel or docetaxel alone. Patient enrollment to ENSPIRIT was initiated by Teva in September 2012. Two interim futility analyses are planned for stopping the trial. The first of these two futility analyses has now been completed which allows for acceleration of further enrollment. A second futility analysis will be conducted later in the trial. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the evaluation of custirsen in the ENSPIRIT trial.

Custirsen is also being evaluated in the ongoing Phase 3 AFFINITY trial with second-line chemotherapy in men with metastatic castrate-resistant prostate cancer. The expected timing of AFFINITY results is based on a pre-specified number of death events, however the Company currently expect final results to be announced in late 2015 or early 2016.

About Custirsen

Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration. By inhibiting clusterin, custirsen is designed to alter tumor dynamics, slowing tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.

As part of Phase 1 and Phase 2 clinical trials, custirsen was administered to 294 patients with various types of cancer. The majority of adverse events were mild. The most common adverse events associated with custirsen consisted of flu-like symptoms. The most common serious adverse events (SAE) associated with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea. Each SAE event was observed in approximately 2%-4% of patients. In the Phase 3 SYNERGY trial in men with metastatic CRPC, adverse events observed were similar to custirsen’s known adverse event profile.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex’ lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company’s Twitter account https://twitter.com/OncoGenex_IR.

OncoGenex’ Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design, statements regarding timing of enrollment and trial completion and statements regarding the potential benefits and potential development of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product, the risk that we are unable to complete enrollment in our clinical trials in the expected timeframe and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Thursday, August 21st, 2014 Uncategorized Comments Off on (OGXI) Update on Phase 3 ENSPIRIT Trial Of Custirsen In Lung Cancer

(PLCE) Partners With Arvind Lifestyle Brands Limited to Expand Into India

SECAUCUS, N.J., Aug. 21, 2014  — The Children’s Place, Inc. (Nasdaq:PLCE), the largest pure-play children’s specialty apparel retailer in North America, today announced that it entered into a franchise agreement with Arvind Lifestyle Brands Limited to open stores in India, with the potential to open 50 stores over time beginning in the Fall of 2015.

Jane Elfers, President and Chief Executive Officer of The Children’s Place, stated, “We are excited to be partnering with Arvind, which has a proven track record of operating successful apparel brands in India. We are making significant strides in our International franchise business, and we remain focused on providing great fashion and value for kids around the world.”

Commenting on the new partnership, Mr. Sanjay Lalbhai, Chairman & Managing Director of Arvind Limited, stated, “The Children’s Place will be the first of its kind children’s retail format in India. It will be a one stop shop for children sizes 0 to 14, and we are delighted to bring The Children’s Place to India.”

About The Children’s Place, Inc.

The Children’s Place is the largest pure-play children’s specialty apparel retailer in North America. The Company designs, contracts to manufacture, sells and licenses to sell fashionable, high-quality merchandise at value prices, primarily under the proprietary “The Children’s Place,” “Place” and “Baby Place” brand names. As of August 2, 2014, the Company operated 1,113 stores in the United States, Canada and Puerto Rico, an online store at www.childrensplace.com, and had 54 International stores open and operated by its franchise partners.

About Arvind Lifestyle Brands Limited

Arvind Lifestyle Brands Limited is a subsidiary of Arvind Limited which is India’s largest integrated textile enterprise and is one of the oldest groups in the textile business in India. Arvind is also one of the largest producers of denim fabric and is supplier to a large number of fashion brands worldwide. Arvind has been a pioneer in bringing international brands to India, beginning in 1993, and has licensing relationships with many U.S. and European brands. Arvind also has its own portfolio of 12 brands, operates the India retail operations of large British retailers and operates India’s largest value retail chain.

Forward Looking Statements

This press release may contain certain forward-looking statements regarding future circumstances, including statements relating to the Company’s strategic initiatives and adjusted net income per diluted share. These forward-looking statements are based upon the Company’s current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results and performance to differ materially. Some of these risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of its annual report on Form 10-K for the fiscal year ended February 1, 2014. Included among the risks and uncertainties that could cause actual results and performance to differ materially are the risk that the Company will be unsuccessful in gauging fashion trends and changing consumer preferences, the risks resulting from the highly competitive nature of the Company’s business and its dependence on consumer spending patterns, which may be affected by the weakness in the economy that continues to affect the Company’s target customer or by other factors such as increases in the cost of gasoline and food, the risk that the Company’s strategic initiatives to increase sales and margin are delayed or do not result in anticipated improvements, the risk that the cost of raw materials or energy prices will increase beyond current expectations or that the Company is unable to offset cost increases through value engineering or price increases, and the uncertainty of weather patterns. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to release publicly any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The inclusion of any statement in this release does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material.

Thursday, August 21st, 2014 Uncategorized Comments Off on (PLCE) Partners With Arvind Lifestyle Brands Limited to Expand Into India

(TRUE) Serving Targeted Manufacturer Incentives To Customers Of Insurance Affinity Partners

TrueCar Helps Automakers More Efficiently Target Their $40 Billion Annual Incentive Spend While Enabling Insurance Partners to Delight Total Loss Customers

SANTA MONICA, Calif., Aug. 21, 2014  — TrueCar, Inc. (NASDAQ: TRUE), the negotiation-free car buying and selling platform, today announced that it has launched major enhancements to the auto buying programs for its insurance affinity partners, specifically the integration of exclusive incentives from automakers uniquely tailored to the needs of total-loss customers. Through the TrueCar platform, automakers now have the ability to deploy marketing resources in a fully accountable manner by offering targeted incentives to customers who suffered a total loss to a vehicle and are unexpectedly in-market for a replacement vehicle. GEICO is the first of TrueCar’s 13 insurance affinity partners to adopt these enhancements, and through the remainder of 2014, TrueCar plans to roll out these platform enhancements to these additional insurance partners, who collectively underwrite over 50% of the automobile policies on the road today.

“More than three million U.S. car owners suffer crashes that result in total losses each year, and most need replacement vehicles right away. Whereas insurance companies have traditionally handed the customer a settlement check and a rental car voucher, TrueCar’s insurance affinity partners are now going above and beyond to help the customer put a new replacement vehicle in the garage and assist them in getting a great deal,” said John Krafcik, TrueCar President. “In addition to helping automakers target their $40 billion incentive budgets, TrueCar enables our insurance affinity partners to provide a delightful customer experience while reducing the incremental costs incurred as a customer recovers from a total-loss event.”

With the new program enhancements, customers of TrueCar’s affinity insurance partners are now able to receive offers and savings directly from participating automakers. In working with their launch partner GEICO and the Chrysler Group, which includes Chrysler, Jeep, Dodge, Ram, and FIAT vehicles, TrueCar has integrated its auto-buying platform with the GEICO claims system to enable eligible GEICO total loss customers to receive a $1,000 incentive on any Chrysler Group vehicle, which can also be combined with other discounts or incentives available at the time of purchase.

“The experience of replacing a total loss vehicle is often a difficult and painful one,” said Jeffrey Kommor, Vice President of U.S Sales Operations for Chrysler Group LLC. “We’re now able to offer total loss customers significant savings on the purchase of a new vehicle, and help make the replacement process much easier for them.”

“We are excited to be the first insurance company to offer this unique targeted incentive with Chrysler to help our customers in time of need to get back on the road quickly,” said Seth Ingall, Senior Vice President at GEICO. “TrueCar’s negotiation-free platform really helps save our customers not only time but also money.”

In addition to exclusive incentives from automakers, TrueCar has also launched an interface that allows insurance affinity partners to integrate TrueCar’s referral tool, called Fast Track, into their claims workflow system. Insurance affinity partners will also be able to take advantage of a new online application that helps total loss customers find their ideal replacement vehicles more quickly and get negotiation-free guaranteed savings off MSRP for new cars at either standard TrueCar Certified Dealers or dealer-owned resource centers that specialize in serving total loss customers.

For more information about TrueCar, please visit www.TrueCar.com, follow @TrueCar on Twitter, or become a fan of TrueCar on Facebook.

About TrueCar
TrueCar, Inc. (NASDAQ: TRUE) is the negotiation-free car buying and selling platform. TrueCar enables a negotiation-free car buying experience by giving buyers transparent insight into what others actually paid (price confidence), upfront pricing information (price discovery), and access to a network of trusted TrueCar Certified Dealers who provide guaranteed savings certificates and seamlessly complete the car purchase. The reality is that buying a car is painful and buyers fear they are going to overpay or be surprised with hidden fees. TrueCar’s transparent upfront pricing information makes the car buying process simple so there are no surprises and buyers never overpay. TrueCar’s mission is to make car buying simple, fair and fun. Its national network of more than 8,000 TrueCar Certified Dealers, including both new car franchise dealers and non-franchise dealers, is committed to providing negotiation-free savings off MSRP and upfront pricing information for all car-buyers, including members of some of the country’s largest membership and service organizations such as AARP, American Express, AAA, and USAA. Note: Not all program features are available in all states. Go to www.truecar.com for program details. TrueCar is headquartered in Santa Monica, Calif., with offices in Santa Barbara, Calif., San Francisco, Calif., and Austin, Texas.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained or referred to in this press release, including statements or references to adoption of enhancements to the TrueCar platform by our partners and the ability of such partners to take advantage of such enhancements are forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions that may prove incorrect, any of which could cause our results to differ materially from those expressed or implied by such forward-looking statements.  Among the risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include: our ability to successfully roll-out program enhancements to additional insurance partners, the rate of adoption of such platform enhancements into their claims workflow, and other risks and uncertainties described more fully under the heading “Risk Factors” in TrueCar’s registration statement on Form S-1 and its quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission. All forward-looking statements included or referred to in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements, which speak only as of their respective dates.

Thursday, August 21st, 2014 Uncategorized Comments Off on (TRUE) Serving Targeted Manufacturer Incentives To Customers Of Insurance Affinity Partners

(AMSC) Receives $15 Million Follow-On Order From Inox Wind

DEVENS, Mass., Aug. 21, 2014  — AMSC (Nasdaq:AMSC), a global solutions provider serving wind and power grid industry leaders, today announced that it has received a $15 million order for wind turbine electrical control systems (ECS) from Inox Wind Limited, part of India’s Inox Group of Companies. The Company expects the majority of shipments under this contract to occur during fiscal year 2015. This is the seventh order that AMSC has received from Inox since the company began volume production of its 2 megawatt (MW) wind turbines, which were licensed from AMSC in May 2009.

“Together with AMSC’s wind turbine design expertise and smart electrical control systems, Inox is delivering wind turbines with some of the highest availability, reliably and power in India,” said Devansh Jain, director of Inox Wind Limited. “We have been successful in growing our business and taking market share in India as we continue to work towards our goal of being the preferred wind solutions provider to independent power producers, utilities, and large corporations.”

According to Bloomberg New Energy Finance (BNEF), India has more than 20 gigawatts (GW) of installed wind capacity. The government recently restored a tax incentive that benefits the wind industry. BNEF expects this incentive to result in wind installations of 2.6 GW in 2014, which would be a three year high for the country. Wind installations are expected to increase steadily to 3.5 GW of installations in 2016.

“The effects of this most recent order from Inox are to extend our existing backlog and provide us greater visibility into fiscal 2015 revenues,” said Daniel P. McGahn, President and CEO, AMSC. “Inox continues to execute on its ambitious growth plan and its planned IPO later this year is expected to provide the capital needed to continue on its path of being a major player in the Indian wind market.”

AMSC’s ECS are an integrated, high-performance suite of power electronics systems that include the wind turbine power converter cabinet, internal power supply and various controls. Together, these systems serve as the “brains” of the wind turbine and enable reliable, high-performance operation by controlling power flows, regulating voltage, monitoring system performance, controlling the pitch of the wind turbine blades and the yaw of the turbines to maximize efficiency.

AMSC reiterates its full year fiscal 2014 expectation of flat to slightly down revenues as compared to fiscal 2013.

About Inox Wind Limited

Inox Wind Limited is part of the Inox Group of Companies. Inox Group is a $2 billion+, professionally managed business group, with interests in diverse businesses including Industrial Gases, Refrigerants, Engineering Plastics, Chemicals, Carbon Credits, Cryogenic Engineering, Renewable Energy and Entertainment. The INOX Group employs close to 9,000 people at more than 150 business units across the country and has a distribution network that is spread across more than 50 countries around the globe. Each INOX Group company is characterized by three distinct characteristics – early identification of a winning business idea, building it to a size of dominant market leadership in that segment, and attaining a profit leadership position through cutting-edge efficiency in operations. The Inox Group of Companies, besides Inox Wind Limited, includes Inox Air Products Limited, Gujarat Fluorochemicals Limited, Inox India Limited, Inox Renewables Limited, Inox Leisure Limited and Fame India limited. More information is available at www.inoxwind.com.

About AMSC (Nasdaq:AMSC)

AMSC generates the ideas, technologies and solutions that meet the world’s demand for smarter, cleaner … better energy. Through its Windtec™ Solutions, AMSC provides wind turbine electronic controls and systems, designs and engineering services that reduce the cost of wind energy. Through its Gridtec™ Solutions, AMSC provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency and performance. The company’s solutions are now powering gigawatts of renewable energy globally and enhancing the performance and reliability of power networks in more than a dozen countries. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe and North America. For more information, please visit www.amsc.com.

AMSC, Windtec, ECS, Gridtec, and Smarter, Cleaner … Better Energy are trademarks or registered trademarks of American Superconductor Corporation. All other brand names, product names, trademarks or service marks belong to their respective holders.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this release regarding the Company’s expectations as to when the majority of shipments will be completed under the Supply Contract; projections regarding wind installations in India; Inox’s ability to provide the capital needed to continue to be a major player in the Indian wind market; expectations regarding fiscal 2014 revenues; and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements represent management’s current expectations and are inherently uncertain. There are a number of important factors that could materially impact the value of our common stock or cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include: We have a history of operating losses, which may continue in the future. Our operating results may fluctuate significantly from quarter to quarter and may fall below expectations in any particular fiscal quarter; we have a history of negative operating cash flows, and we may require additional financing in the future, which may not be available to us; Our Term Loans include certain covenants and other events of default. Should we not comply with these covenants or incur an event of default, we may be required to repay our obligation in cash, which could have an adverse effect on our liquidity; We may be required to issue performance bonds or provide letters of credit, which restricts our ability to access any cash used as collateral for the bonds or letters of credit; Changes in exchange rates could adversely affect our results from operations; If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired and may lead investors and other users to lose confidence in our financial data; Our success in addressing the wind energy market is dependent on the manufacturers that license our designs; Our success is dependent upon attracting and retaining qualified personnel and our inability to do so could significantly damage our business and prospects; We may not realize all of the sales expected from our backlog of orders and contracts; Our financial condition may have an adverse effect on our customer and supplier relationships; Failure to successfully execute the consolidation of our Grid manufacturing operations or achieve expected savings could adversely impact our financial performance; Our business and operations would be adversely impacted in the event of a failure or security breach of our information technology infrastructure; We may not be able to launch operations at our newly leased manufacturing facility in Romania, and, if we are able to do so, we may have manufacturing quality issues, which would negatively affect our revenues and financial position; We rely upon third-party suppliers for the components and subassemblies of many of our Wind and Grid products, making us vulnerable to supply shortages and price fluctuations, which could harm our business; Many of our revenue opportunities are dependent upon subcontractors and other business collaborators; If we fail to implement our business strategy successfully, our financial performance could be harmed; Problems with product quality or product performance may cause us to incur warranty expenses and may damage our market reputation and prevent us from achieving increased sales and market share; New regulations related to conflict-free minerals may force us to incur significant additional expenses; Our contracts with the U.S. government are subject to audit, modification or termination by the U.S. government and include certain other provisions in favor of the government. The continued funding of such contracts remains subject to annual congressional appropriation which, if not approved, could reduce our revenue and lower or eliminate our profit; Many of our customers outside of the United States are, either directly or indirectly, related to governmental entities, and we could be adversely affected by violations of the United States Foreign Corrupt Practices Act and similar worldwide anti-bribery laws outside the United States; We have limited experience in marketing and selling our superconductor products and system-level solutions, and our failure to effectively market and sell our products and solutions could lower our revenue and cash flow; We may acquire additional complementary businesses or technologies, which may require us to incur substantial costs for which we may never realize the anticipated benefits; Our success depends upon the commercial use of high temperature superconductor (HTS) products, which is currently limited, and a widespread commercial market for our products may not develop; Growth of the wind energy market depends largely on the availability and size of government subsidies and economic incentives; We have operations in and depend on sales in emerging markets, including China and India, and global conditions could negatively affect our operating results or limit our ability to expand our operations outside of these countries. Changes in China’s or India’s political, social, regulatory and economic environment may affect our financial performance; Our products face intense competition, which could limit our ability to acquire or retain customers; Our international operations are subject to risks that we do not face in the United States, which could have an adverse effect on our operating results; Adverse changes in domestic and global economic conditions could adversely affect our operating results; We may be unable to adequately prevent disclosure of trade secrets and other proprietary information; Our patents may not provide meaningful protection for our technology, which could result in us losing some or all of our market position; There are a number of technological challenges that must be successfully addressed before our superconductor products can gain widespread commercial acceptance, and our inability to address such technological challenges could adversely affect our ability to acquire customers for our products; We have not manufactured our Amperium wire in commercial quantities, and a failure to manufacture our Amperium wire in commercial quantities at acceptable cost and quality levels would substantially limit our future revenue and profit potential; Third parties have or may acquire patents that cover the materials, processes and technologies we use or may use in the future to manufacture our Amperium products, and our success depends on our ability to license such patents or other proprietary rights; Our technology and products could infringe intellectual property rights of others, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and disrupt our business; We have filed a demand for arbitration and other lawsuits against our former largest customer, Sinovel, regarding amounts we contend are overdue. We cannot be certain as to the outcome of these proceedings; We have been named as a party in various legal proceedings, and we may be named in additional litigation, all of which will require significant management time and attention, result in significant legal expenses and may result in an unfavorable outcome, which could have a material adverse effect on our business, operating results and financial condition; Our common stock has experienced, and may continue to experience, significant market price and volume fluctuations, which may prevent our stockholders from selling our common stock at a profit and could lead to costly litigation against us that could divert our management’s attention.

These and the important factors discussed under the caption “Risk Factors” in Part 1. Item 1A of our Form 10-K for the fiscal year ended March 31, 2014, and our other reports filed with the SEC, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: AMSC Contact:
         Kerry Farrell
         Phone: 978-842-3247
         Email: kerry.farrell @ amsc.com
Thursday, August 21st, 2014 Uncategorized Comments Off on (AMSC) Receives $15 Million Follow-On Order From Inox Wind

(EVRY) Agrees to Sell UK Business

LANCASTER, Ohio, Aug. 21, 2014  — EveryWare Global, Inc. (“EveryWare” or the “Company”) (Nasdaq:EVRY), today announced that its wholly-owned subsidiary Oneida International has entered into an agreement to sell its United Kingdom business to HUK 54 Limited. EveryWare retains all rights to the brands ONEIDA®, Anchor Hocking® and Sant’ Andrea®.

Sam Solomon, Chief Executive Officer of EveryWare, stated, “This transaction represents another step toward building a profitable future for EveryWare. We are confident that there remain long-term opportunities to build and grow our brands internationally. Our energies are currently focused on solidifying our core North American operations, and this sale ensures that our resources are dedicated to those initiatives.”

For additional detail on the transaction, please refer to the Form 8-K filed today with the Securities and Exchange Commission.

About EveryWare

EveryWare (Nasdaq:EVRY) is a leading marketer of tabletop and food preparation products for the consumer, foodservice, and specialty markets. The Company offers a comprehensive line of tabletop and food preparation products, such as bakeware, beverageware, serveware, storageware, flatware, dinnerware, crystal, banquetware, and hollowware; premium spirit bottles; cookware; gadgets; candle and floral glass containers; and other kitchen products. Additional information can be found on EveryWare’s Investor Relations Website: http://investors.everywareglobal.com/.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”). All statements other than statements of historical facts are statements that could be deemed forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the industries in which we operate and the beliefs and assumptions of our management. Words such as “tentative,” “proposal,” “offers,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “continues,” “endeavors,” “strives,” “may,” variations of such words, and similar expressions are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, covenant compliance, liquidity and other characterizations of future events or circumstances are forward-looking statements.

Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason. For a description of the risks, uncertainties, and assumptions that may impact our actual results or performance, see the Company’s Annual Report on Form 10-K for 2013, filed with the Securities and Exchange Commission, as it may be updated in subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission.

CONTACT: Erica Bartsch
         Sloane & Company
         ebartsch@sloanepr.com
Thursday, August 21st, 2014 Uncategorized Comments Off on (EVRY) Agrees to Sell UK Business

(PBCP) Retirement of Chief Executive Officer and Appointment of Interim CEO

Polonia Bancorp, Inc. (the “Company”) (NASDAQ Capital Market: PBCP), the holding company of Polonia Bank (the “Bank”), announced today that Anthony J. Szuszczewicz advised the Board of Directors that he is retiring as President and Chief Executive Officer and from the Boards of Directors of the Company and the Bank effective August 31, 2014. The Company accepted Mr. Szuszczewicz’ retirement letter and thanked him for his years of service and leadership. Because of his strong ties to the communities in which the Bank operates, Mr. Szuszczewicz is expected to continue to be affiliated with the Bank in an advisory role.

The Company also announced that the Board of Directors has appointed Paul D. Rutkowski, the Company’s Chief Financial Officer, to the position of Chief Executive Officer on an interim basis while the Board of Directors conducts a search for a permanent President and Chief Executive Officer. Mr. Rutkowski has served as Chief Financial Officer of Polonia Bank since 2005 and Corporate Secretary since 2006. Mr. Rutkowski served as Controller and Treasurer of Polonia Bank from 1992 to 2005 and has served as Chief Financial Officer and Corporate Secretary of Polonia Bancorp (and its predecessor) since 2007.

The Bank also announced today that the Board of Directors voted Robert J. Woltjen, a current director, as the Chairman of the Board of the Company and the Bank, replacing Mr. Szuszczewicz.

Polonia Bancorp, Inc. is the holding company for Polonia Bank. Polonia Bank is headquartered in Huntingdon Valley, Pennsylvania and has provided community banking services to customers for almost 91 years. We currently operate five full-service locations in Montgomery and Philadelphia Counties, Pennsylvania.

Wednesday, August 20th, 2014 Uncategorized Comments Off on (PBCP) Retirement of Chief Executive Officer and Appointment of Interim CEO

(IDN) Lenel Factory Certification under Lenel’s OpenAccess Alliance Program

Intellicheck Mobilisa Inc. (NYSE MKT:IDN), a global leader in identity solutions and wireless security systems, has received Lenel factory certification and joined the Lenel OpenAccess Alliance Program (OAAP). Intellicheck Mobilisa’s mobile handheld readers IM2610, IM2620 and IM2800h interface with the Lenel OnGuard access control system and allow a security guard to scan a security badge and check access permissions from the OnGuard security platform in areas where there is no connectivity available.

“Intellicheck Mobilisa has completed required factory testing at Lenel to validate the functionality of its interface to the OnGuard system. By making ‘offline’ security badge validation possible, their mobile handheld readers offer a new level of convenience to security guards and badge holders alike,” said Gidon Lissai, director of strategic alliances, Lenel. “We look forward to their continued involvement in the Lenel OpenAccess Alliance Program.”

“Interfacing with Lenel’s OnGuard access control security system demonstrates the versatility of our mobile handheld readers and provides us the opportunity to showcase our technology to a new market segment,” stated Nelson Ludlow, president and CEO of Intellicheck Mobilisa. “We are grateful for the opportunity to work with Lenel and look forward to working together in the future.”

A link to Intellicheck Mobilisa’s Mobile Reader follows:

http://www.lenel.com/solutions/open-integration/oaap/partners-products-search/intellicheck-mobilisa-mobile-reader

About Intellicheck Mobilisa

Intellicheck Mobilisa is a leading technology company providing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. Products include the Fugitive Finder system, an advanced ID card access control product currently protecting military bases and secure federal locations; ID Check, a patented technology that instantly reads, analyzes, and verifies encoded data in magnetic stripes and barcodes on government-issued IDs, designed to improve the Customer Experience for the financial, hospitality and retail sectors; barZapp™, an ID-checking mobile app that allows a user’s smartphone to check an ID card. For more information on Intellicheck Mobilisa, please visit www.icmobile.com.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. When used in this press release, words such as “will,” “believe,” “expect,” “anticipate,” “encouraged,” and similar expressions, as they relate to the company or its management, as well as assumptions made by and information currently available to the company’s management identify forward-looking statements. Actual results may differ materially from the information presented here. Additional information concerning forward-looking statements is contained under the heading of risk factors listed from time to time in the company’s filings with the SEC. We do not assume any obligation to update the forward-looking information.

Lenel and OnGuard are registered trademarks of Lenel Systems International Inc. in the United States and/or other countries.

Wednesday, August 20th, 2014 Uncategorized Comments Off on (IDN) Lenel Factory Certification under Lenel’s OpenAccess Alliance Program

(HPJ) To Power Timex Smartwatches w/ Advanced, Compact Rechargeable Lithium Batteries

SAN FRANCISCO and SHENZHEN, China, Aug. 20, 2014  — Highpower International, Inc. (NASDAQ: HPJ), a developer, manufacturer, and marketer of lithium and nickel-metal hydride (Ni-MH) rechargeable batteries, and a battery management systems and battery recycling provider, today announced that it started shipping its advanced compact lithium battery product developed for the newly introduced TIMEX® IRONMAN® ONE GPS+, a smartwatch offering consumers stand-alone wireless connectivity without a phone.

Mr. George Pan, Chairman and CEO of Highpower, commented, “Timex is an iconic watch brand. We are excited to work with Timex as a contributor to this innovative smartwatch technology. We feel that wearables represent an exciting area of growth for mobile devices, and smartwatches could provide a natural progression from current applications to help consumers further embrace wearable technology. We feel that our battery performance, seamlessness of services, and quality will allow us to compete for a proportionate market share of batteries for these products. Highpower is a flexible battery manufacturer capable of applying our expertise to a number of different markets, and this initial order is strong evidence that our product offering is gaining traction in the rapidly growing wearable device market.”

The TIMEX® IRONMAN® ONE GPS+ will be available for purchase this fall at timex.com, att.com, AT&T stores, select sports specialty and electronic stores.

About Highpower International, Inc.

Highpower International was founded in 2001 and produces high-quality Nickel-Metal Hydride (Ni-MH) and lithium-based rechargeable batteries used in a wide range of applications such as electric buses, bikes, energy storage systems, power tools, medical equipment, digital and electronic devices, personal care products, and lighting, etc. Highpower’s target customers are Fortune 500 companies, and top 10 companies in each vertical segment. With advanced manufacturing facilities located in Shenzhen, Huizhou, and Ganzhou of China, Highpower is committed to clean technology, not only in the products it makes, but also in the processes of production. The majority of Highpower International’s products are distributed to worldwide markets mainly in the United States, Europe, China and Southeast Asia.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company’s future performance, operations and products. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results to differ materially from the results expressed or implied by such statements. For a discussion of these and other risks and uncertainties see “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s public filings with the SEC. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

CONTACT:

Highpower International, Inc.
Fendi Yang
+86-755-8968-6521
ir@highpowertech.com

INVESTOR RELATIONS:

The Equity Group Inc.
In China
Katherine Yao, Associate
+86-10-6587-6435
kyao@equityny.com

In U.S.
Adam Prior, Senior Vice President
(212) 836-9606
aprior@equityny.com

Wednesday, August 20th, 2014 Uncategorized Comments Off on (HPJ) To Power Timex Smartwatches w/ Advanced, Compact Rechargeable Lithium Batteries

(FOLD) Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function

Comparability to ERT Also Demonstrated in Important Fabry Disease Biomarker, Plasma Lyso-Gb3

Proceeding with Centralized Procedure for European MAA Submission

Conference Call and Webcast Today at 8:00 a.m. ET

CRANBURY, N.J., Aug. 20, 2014  — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced positive 18-month data from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl (“migalastat”) in Fabry patients with amenable mutations. Detailed results of this second Phase 3 monotherapy study are available in a slide presentation that will be shared by the Amicus management team on a conference call today at 8:00 a.m. ET. Please visit http://ir.amicustherapeutics.com/events.cfm.

Study 012 compared oral migalastat to standard-of-care enzyme replacement therapies (ERTs) for Fabry disease (Fabrazyme® and Replagal®). The co-primary outcome measures were the mean annualized changes in estimated glomerular filtration rate (eGFR) and measured (iohexol) GFR (mGFR) assessed by descriptive comparisons of migalastat and ERT over 18 months. The study enrolled 60 patients (26 males and 34 females) with Fabry disease with amenable mutations in a clinical trial assay who had been treated with ERT for a minimum of 12 months prior to study entry. These patients were randomized 1.5:1 to switch to migalastat (36 patients) or remain on ERT (24 patients) for the primary 18-month treatment period, after which they were eligible to receive migalastat in a 12-month extension phase. Among the 60 patients enrolled, 56 (34 in the migalastat group and 22 in the ERT group) had amenable mutations in a GLP-validated human embryonic kidney (HEK) cell-based in vitro assay (“GLP HEK-amenable”). The statistical analysis plan pre-specified that all efficacy measures would be based on the results from patients with GLP HEK-amenable mutations.

Summary of Study 012 18-Month Results

  • Migalastat had a comparable effect to ERT on patients’ kidney function as measured by the change in eGFR and mGFR.
  • Levels of plasma lyso-Gb3, an important biomarker of disease, remained low and stable in patients with amenable mutations who switched from ERT to migalastat.
  • Migalastat was generally safe and well-tolerated.
  • Of 48 patients with GLP HEK-amenable mutations who completed Study 012, 46 (96%) elected to continue with the 12-month treatment extension and 45 remain on migalastat today as their only treatment for Fabry disease.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “We believe that this multi-year study unequivocally demonstrates that a Fabry patient on ERT with an amenable mutation can switch safely and effectively from ERT to migalastat to treat their Fabry disease. Today is a great day for the Fabry community and for Amicus. This study was resoundingly positive and met our pre-defined criteria for success in terms of the co-primary endpoints of kidney function. These results clearly show that migalastat is comparable to ERT in slowing the progression of Fabry disease and continues to demonstrate a favorable safety profile. With every-other-day oral administration and a differentiated mechanism of action, migalastat may offer significant advantages for patients without the need for bi-weekly infusions with ERT. Combined with our previous Phase 3 results from Study 011, we have a compelling and consistent data set from both treatment-naïve and ERT-experienced patients. Given these results and the great need for new and effective medicines, we plan to work with European and U.S. regulators to determine the fastest way to get migalastat approved for all amenable Fabry patients.”

Raphael Schiffmann, M.D., M.H.Sc., an investigator with the Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX stated, “I believe the results from Study 012 show a positive treatment effect of migalastat in Fabry patients with amenable mutations. The stabilization of renal function and the maintenance of substrate levels as measured by lyso-Gb3 provide further clinical evidence that supports my experience over the last eight years in treating Fabry patients with migalastat in various clinical studies. When combined with the favorable safety profile, the totality of the data from Study 012 and Study 011 indicate that migalastat should become an important new oral treatment option for Fabry patients.”

Dr. Schiffmann added, “Given the choice, I would use migalastat over ERT for the treatment of Fabry patients with amenable mutations.”

Study 012 Kidney Function Data in GLP HEK-Amenable Patients

Among patients with GLP HEK-amenable mutations in Study 012, kidney function was comparable to ERT over 18 months following treatment with migalastat. Decline in kidney function is a key cause of mortality in patients with Fabry disease.

Overlap of
95%
Confidence
Intervals
Difference
Between
Migalastat
and ERT
Mean Values ± SEM Median Values
(means) (means) Migalastat group
(n=34)
ERT group
(n=18)
Migalastat group
(n=34)
ERT group
(n=18)
Estimated
GFR (eGFR)
(CKD-epi)
100% +0.63  -0.40 ± 0.93  -1.03± 1.29  -1.29 -0.87
Measured
GFR (mGFR)
(iohexol)
100% -1.11  -4.35 ± 1.64  -3.24 ± 2.27 -3.23 -3.57

As pre-specified in the final statistical analysis plan, the co-primary outcome measures of efficacy in Study 012 were the descriptive assessments of comparability of the mean annualized change in eGFR and mGFR for migalastat and ERT. Both eGFR and mGFR are considered important measures of renal function. Comparability on eGFR and mGFR was defined in two ways:

  • A ≥50% overlap in the confidence intervals between the migalastat and ERT treatment groups; and
  • Whether the mean annualized changes for patients receiving migalastat are within 2.2 mL/min/1.73 m2/yr of patients receiving ERT.

“These data mark an exciting day for the Fabry community and validate our long-term commitment to work in partnership with industry toward our goal of multiple treatment options and improved medicines for all people living with Fabry disease,” said Jack Johnson, Founder and Executive Director, Fabry Support & Information Group. “We await the regulatory agencies’ review of these data, and we are grateful to the many people with Fabry disease, families and volunteers who have committed so much of themselves to help accelerate efforts to bring a more convenient and effective therapy to people living with the disease.”

About GLP HEK-Amenable Mutations

Amenable mutations are defined as having an absolute increase of 3% of wild type alpha-Gal A enzyme activity and a relative increase of 20% when exposed to migalastat in a cell-based in vitro assay. All patients enrolled in Study 012 had amenable mutations in the clinical trial HEK assay available at study initiation (“clinical trial assay”). Following the completion of enrollment, a GLP HEK assay was developed with a third party to measure the criteria for amenability with more quality control and rigor. However, approximately 10% of mutations in the HEK database switched categorization between “amenable” and “non-amenable” when moving from the clinical trial assay to the GLP HEK assay. Therefore there were changes in categorization from amenable to non-amenable in 4 patients in Study 012.

Overall based on results from mutations tested in the GLP HEK assay, Amicus continues to believe that approximately 30% to 50% of the Fabry population have mutations that are amenable to migalastat.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and audio webcast today, August 20, 2014 at 8:00 a.m. ET to discuss positive results from Study 012. Interested participants and investors may access the conference call at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). The slide presentation for the conference call is available at http://ir.amicustherapeutics.com/events.cfm.

An audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 11:00 a.m. ET today. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 90825426.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.

Forward-Looking Statements

This press release contains, and the accompanying conference call will contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus’ candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products and the projected cash position for the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company’s cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media:
         Chip Baird
         cbaird@amicusrx.com
         (609) 662-2063

         Media:
         Dan Budwick
         dan@purecommunicationsinc.com
         (973) 271-6085
Wednesday, August 20th, 2014 Uncategorized Comments Off on (FOLD) Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

(CPAH) Contract/Strategic Channel Agreement w/ Large Network Equipment Provider

Company leverages patent portfolio and success of Operator and Enterprise Over the Top (OTT) deployments to secure an agreement to sell CounterPath’s unified communications solution to operators worldwide

VANCOUVER, BRITISH COLUMBIA–(Aug 20, 2014) – CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), a leading developer of award-winning UC over-the-top (OTT) solutions for desktop, tablet and mobile solutions for operators and enterprises, today announced that a major supplier of networking equipment and solutions has signed a definitive agreement with the company to market and sell CounterPath’s OTT communications solutions to operators worldwide.

Enterprise and Operator OTT solutions are key for customers that want to differentiate their UC and IMS (IP Multimedia Subsystem) based deployments. In the case of deployments like Rogers One Number, operators have experienced a positive upturn in subscriber growth and reduced usage of Internet OTT services such as Skype or Apple’s Facetime.

“Carriers and Enterprises are looking for market tested Unified Communications solutions that they can confidently roll out to their end users,” said Donovan Jones, President and Chief Executive Officer. “By taking our client-centric, platform agnostic approach and extending it to our server platform we can offer a solution which not only overlays to any network deployment but greatly enhances the user experience, providing a highly differentiated service for operators and enterprises. This new relationship opens up a significant market opportunity for CounterPath, once again demonstrating the industry’s trust in the value and reliability of our applications and solutions.”

The signed agreement covers all of CounterPath’s products and services that comprise Operator and Enterprise OTT solutions enabling voice, video, presence and messaging over the most popular operating systems and devices across any IP network.

About CounterPath

CounterPath’s SIP-based VoIP softphones are changing the face of telecommunications. An industry and user favorite, Bria softphones for desktop and mobile devices, together with the Company’s server applications and Fixed Mobile Convergence (FMC) solutions, enable service providers, OEMs and enterprises large and small around the globe to offer a seamless and unified communications experience across both fixed and mobile networks. Standards-based, cost-effective and reliable, CounterPath’s award-winning solutions power the voice and video calling, messaging, and presence offerings of customers such as Alcatel-Lucent, AT&T, Avaya, BroadSoft, BT, Cisco Systems, GENBAND, Metaswitch Networks, Mitel, NEC, Network Norway, Rogers and Verizon.

For more information about CounterPath’s Bria softphone applications and provisioning solutions, visit: www.counterpath.com/products.

CounterPath Corporation
Kasia Finkelstein
Marketing & PR
(604) 628-9378
kfinkelstein@counterpath.com
CounterPath Corporation
Steven Hards
Investor Relations
(604) 637-6498
shards@counterpath.com
www.counterpath.com

Wednesday, August 20th, 2014 Uncategorized Comments Off on (CPAH) Contract/Strategic Channel Agreement w/ Large Network Equipment Provider

(GSIT) Receives Unsolicited Acquisition Proposal

SUNNYVALE, CA–(Aug 19, 2014) – GSI Technology, Inc. (NASDAQ: GSIT) today announced that it has received from GigOptix, Inc. an unsolicited, non-binding and conditional proposal to acquire the company for per share consideration of $6.50 per share consisting of a combination of cash and GigOptix common stock.

GSI Technology’s Board of Directors will promptly and carefully review and consider the GigOptix proposal consistent with its fiduciary duties and in consultation with its financial and legal advisors. Following its review, the GSI Technology Board will respond to the proposal and advise its stockholders of the Board’s response.

About GSI Technology
Founded in 1995, GSI Technology, Inc. is a leading provider of high-performance static random access memory, or SRAM, products primarily incorporated in networking and telecommunications equipment. Headquartered in Sunnyvale, California, GSI Technology is ISO 9001 certified and has worldwide factory and sales locations. For more information, please visit www.gsitechnology.com.

Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements included in this press release are based upon information available to GSI Technology as of the date hereof, and GSI Technology assumes no obligation to update any such forward-looking statements. Forward-looking statements involve a variety of risks and uncertainties, which could cause actual results to differ materially from those projected. These risks include the possibility that the unsolicited proposal by GigOptix may not be supported by the GSI Technology Board and that one or more of the conditions to the proposal may not be satisfied. Further information regarding other risks relating to GSI Technology’s business is contained in the Company’s filings with the Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in such filings.

GSI Technology, Inc.
Douglas Schirle
Chief Financial Officer
408-331-9802

Tuesday, August 19th, 2014 Uncategorized Comments Off on (GSIT) Receives Unsolicited Acquisition Proposal

(CLIR) Contracts with Aera Energy On Next-Gen NOx Control Tech

SEATTLE, Aug. 19, 2014  — ClearSign Combustion Corporation <http://www.clearsign.com/> (NASDAQ: CLIR), an emerging leader in combustion and emissions control technology for industrial, commercial and utility markets, announced today that it has entered into a Field Test Agreement withAera Energy LLC <http://www.aeraenergy.com/who-we-are.asp> to demonstrate and test its proprietary Duplex™ tile combustion technology in oil fields located inKern County in central California.

The agreement also specifies pricing and delivery conditions that would apply if Aera purchases an agreed upon number of systems if ordered and installed within a specified period of time following successful completion of the demonstration and tests.

Under the terms of the agreement, ClearSign and its subcontracted field engineering team will retrofit an existing steam generator unit with ClearSign’s Duplex tile technology to test capability to achieve ultra-low emissions (5 ppm) of nitrogen oxides, or NOx. The Duplex will be paired with an existing forced draft burner and will operate at a heat release of 30 to 60 MMBtu/hr (roughly equivalent to 9 to 18 MW). This will represent the largest scale demonstration under process conditions of the company’s Duplex tile technology to date.

ClearSign plans to begin the project before the end of the current quarter.

As testing progresses, ClearSign will provide additional detail regarding their plans to enter the OTSG market, including identifying distribution partners.

About Enhanced Oil Recovery (EOR)

The so-called “heavy oil” that comprises the oil sand reserves in areas like theSan Joaquin Valley and Alberta, Canada is so thick that its viscosity must be reduced in order to recover, process or transport it. Steam is generated in large units called once through steam generators (OTSGs) and then pumped into the oil reservoir to heat the oil to allow it flow more easily.

Worldwide, 96.5% of Enhanced Oil Recovery (EOR) is performed via steam generation, of which 65% occurs inNorth America alone. In the United States, 94% of EOR occurs inCalifornia’s San Joaquin Valley where 303,000 barrels per day (bpd) of oil are produced using 768 OTSGs, each averaging ~ 60 MMBtu/hr. InCanada, virtually all EOR occurs in Northern Alberta where almost four times (1.2 million bpd) the amount of oil is produced using 250 much larger OTSGs, each of which is over ~ 250 MMBtu/hr. Retrofit activity is expected to be a key market driver inthe United States where the San Joaquin Valley Air Pollution Control District’s Reg. 4320 mandates reductions in NOx to 9ppm or below. According to Visiongain, an explosion in new-build activity will characterize the market inNorthern Alberta with the number of very large OTSGs expected to almost triple – to over 650 units – by 2023.

Note the existence of this agreement was disclosed during the Company’s second quarter results call onAugust 12, 2014, however this announcement contains new information, including identifying Aera Energy LLC and other details.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. Our Duplex™ Burner Architecture and Electrodynamic Combustion Control™ (ECC™) platform technologies improve control of flame shape and heat transfer and optimize the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information about the Company, please visitwww.clearsign.com <http://www.clearsign.com/>

Cautionary note on forward-looking statements

This press release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management’s belief, as well as assumptions made by, and information currently available to, management. While we believe that our expectations are based upon reasonable assumptions, there can be no assurances that our goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect our actual results and may cause results to differ materially from those expressed in forward-looking statements made by us or on our behalf. Some of these factors include the acceptance of existing and future products, the impact of competitive products and pricing, general business and economic conditions, and other factors detailed in our Quarterly Report on Form 10-Q and other periodic reports filed with the SEC. We specifically disclaim any obligation to update or revise any forward-looking statement whether as a result of new information, future developments or otherwise.

Tuesday, August 19th, 2014 Uncategorized Comments Off on (CLIR) Contracts with Aera Energy On Next-Gen NOx Control Tech

(SYN) Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC

— Two of Company’s Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C. difficile —

ROCKVILLE, Md., Aug. 19, 2014  — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel C. difficile development program will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.

Synthetic Biologics’ Senior Vice President, Research & Development, Mike Kaleko, M.D., Ph.D., will present a late-breaking poster related to the Company’s C. difficile program. The poster will be available for viewing in Exhibit Hall A on Saturday, September 6, from 12:00pm to 2:00pm Eastern Time, as part of the “Agents Targeting Clostridium difficile” session.

Title: P4A, a Novel Oral Beta-Lactamase for the Prevention of Cephalosporin-Induced C. difficile Infection
Authors1: M. Kaleko, J. A. Bristol, S. Connelly, P. Koski
Poster: F-250c

“We are thrilled to have the opportunity to present research from our novel C. difficile program at ICAAC. This conference is known for its high academic standards and draws the infectious disease field’s foremost leaders. We look forward to presenting our findings that support the development of our prophylactic to protect the GI microflora from the effects of certain IV antibiotics for the prevention of C. difficile infection,” stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “This scientific presentation is very relevant, as we continue to advance our innovative C. difficile program toward clinical trials during 2014.”

The Company previously announced that Synthetic Biologics’ academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin’s McKetta Department of Chemical Engineering will highlight Synthetic Biologics’ SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis (whooping cough) in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the “Neonatal Infections and the Case for Maternal Immunization” session.

Title: Rational Design of Antibody Cocktails to Treat Disease Caused by Bordetellae
Authors: M. Kaleko1, A. Nguyen2, E. Wagner2, J. Laber2, L. Goodfield3, W. Smallridge3, E. T. Harvill3, R. F. Wolf4, J. C. Papin4, J. A. Maynard2

1Synthetic Biologics, Rockville, MD, 2Universty of Texas at Austin, Austin, TX, 3Penn State Univ., University Park, PA, 4Univ. of Oklahoma Hlth. Sci. Ctr., Oklahoma City, OK

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding Synthetic Biologics’ continued advancement of its C. difficile program toward clinical trials. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, the additional clinical studies and results not meeting expectations and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Tuesday, August 19th, 2014 Uncategorized Comments Off on (SYN) Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC

(SLXP) Announces Early Termination of HSR Waiting Period for Pending Transaction

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that it has received notice of the early termination of the waiting period for U.S. antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its previously announced combination transaction with Cosmo Pharmaceuticals S.p.A. (SIX: COPN). The waiting period was scheduled to expire on August 21, 2014. Termination of the waiting period satisfies a condition to the closing of the transaction. Completion of the transaction remains subject to approval by Salix’s stockholders and certain other closing conditions.

About Salix

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force.

Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution, 100 g/7.5 g/2.691 g/1.015 g/5.9 g/4.7 g), OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) tablets, APRISO® (mesalamine) extended-release capsules 0.375 g, UCERIS® (budesonide) extended release tablets, for oral use, GIAZO® (balsalazide disodium) tablets, COLAZAL® (balsalazide disodium) Capsules, GLUMETZA® (metformin hydrochloride extended-release tablets) 500 mg and 1000 mg, ZEGERID® (omeprazole/sodium bicarbonate) Powder for Oral Suspension, ZEGERID® (omeprazole/sodium bicarbonate) capsules, METOZOLV® ODT (metoclopramide hydrochloride), RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, FULYZAQ® (crofelemer) delayed-release tablets, SOLESTA®, DEFLUX®, RUCONEST® (C1 esterase Inhibitor (Recombinant) 50 IU/kg, PEPCID® (famotidine) for Oral Suspension, DIURIL® (chlorothiazide) Oral Suspension, AZASAN® (azathioprine) tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg, CYCLOSET®(bromocriptine mesylate) tablets, FENOGLIDE® (fenofibrate) tablets. UCERIS (budesonide) rectal foam, RELISTOR®, encapsulated bowel preparation and rifaximin for additional indications are under development.

For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP, AZASAN, GLUMETZA and METOZOLV, please visit www.salix.com, where Salix promptly posts press releases, SEC filings and other important information, or contact Salix at (919) 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.

For more information, please visit our Website at www.salix.com or contact Salix at (919)-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our filings with the SEC.

About Cosmo

Cosmo Pharmaceuticals S.p.A. is a specialty pharmaceutical company headquartered in Lainate, Italy. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for the gastrointestinal tract, specifically inflammatory bowel diseases, colon infections and colon diagnosis, as well as selected topically treated skin disorders. Cosmo’s proprietary MMX® technology, designed to deliver active ingredients in a targeted manner in the colon, is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. Currently, Cosmo, through its appointed partners, has three products on the market and six in clinical development. For further information on Cosmo, please visit the Company’s website: www.cosmopharma.com.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction pursuant to the merger or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Cautionary Statement Regarding Forward-Looking Statements

As previously announced on July 8, 2014, Salix, Cosmo Pharmaceuticals S.p.A. and Irish domiciled Cosmo Technologies Limited entered into an Agreement and Plan of Merger and Reorganization, pursuant to which a subsidiary of Cosmo Technologies Limited will merge with and into Salix, with Salix as the surviving entity, and Salix will become an indirect, wholly-owned subsidiary of Cosmo Technologies Limited, which will change its name to Salix Pharmaceuticals, plc.

Please Note: The statements provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, our expectations might not be attained. Forward-looking statements are just predictions and are subject to known and unknown risks and uncertainties that could cause actual events or results to differ materially from expected results. Factors that could cause actual events or results to differ materially from those described herein include, among others: uncertainties as to the ability to successfully complete the proposed transaction in accordance with its terms and in accordance with the expected schedule; the possibility that competing offers will be made; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit or refuse to grant any approval required for the consummation of the proposed transaction; the unpredictability of the duration and results of regulatory review of New Drug Applications, Biologics License Agreements, and Investigational NDAs; generic and other competition in an increasingly global industry; litigation and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties in an increasingly global industry; the cost, timing and results of clinical trials and other development activities involving pharmaceutical products; post-marketing approval regulation, including the ongoing Department of Justice investigation of Salix’s marketing practices; market acceptance for approved products; revenue recognition and other critical accounting policies; the need to acquire new products; changes in tax laws or interpretations thereof; general economic and business conditions; and other factors. Readers are cautioned not to place undue reliance on the forward-looking statements included herein, which speak only as of the date hereof. Salix does not undertake to update any of these statements in light of new information or future events, except as required by law. The reader is referred to the documents that Salix files from time to time with the SEC.

Important Additional Information and Where to Find It

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction and required stockholder approval, Cosmo Pharmaceuticals S.p.A., Cosmo Technologies Limited and Salix will file relevant materials with the SEC, including a proxy statement/prospectus contained in a registration statement on Form S-4, which will be mailed to the stockholders of Salix after the registration statement is declared effective. The registration statement has not yet become effective.

SALIX STOCKHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT/PROSPECTUS, AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TRANSACTION, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

Salix stockholders may obtain a free copy of the proxy statement/prospectus, when it becomes available, and other documents filed by Salix at the SEC’s web site at www.sec.gov. Copies of Salix’s filings with the SEC may be obtained free of charge at the “Investors” section of Salix’s website at www.salix.com or by contacting the Investor Relations Department of Salix at 919-862-1000.

Participants in the Solicitation

Salix and its directors, executive officers and certain other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed transaction. Information regarding the interests of such directors and executive officers was included in Salix’s Proxy Statement for its 2014 Annual Meeting of Stockholders filed with the SEC on April 28, 2014 and information concerning the participants in the solicitation will be included in the proxy statement/prospectus relating to the proposed transaction when it becomes available. Each of these documents is, or will be, available free of charge at the SEC’s website at www.sec.gov and from Salix on its website or by contacting the Investor Relations Department at the telephone number above.

Tuesday, August 19th, 2014 Uncategorized Comments Off on (SLXP) Announces Early Termination of HSR Waiting Period for Pending Transaction

(HGSH) Signed its First Shanty Area Rebuilding Project Agreement

HANZHONG, China, Aug. 19, 2014  — China HGS Real Estate, Inc. (NASDAQ: HGSH) (“China HGS” or the “Company”), a leading regional real estate developer headquartered in Hanzhong City, Shaanxi Province, China, today announced that the Company signed its first shanty area rebuilding framework agreement with the Hantai District government of Hanzhong City.

Pursuant to the agreement, the Company is engaged in developing the shanty areas surrounding Liang Zhou Road located in the Hantai District, Hanzhong City. The estimated investment in the project is approximately US$580 million. The local government will coordinate with the Company to implement the reform plan.

“We are excited about signing the Liang Zhou Road shanty area rebuilding project agreement,” said Mr. Xiaojun Zhu, Chief Executive Officer of China HGS Real Estate, Inc. “As a leading regional real estate developer, we believe that the rebuilding plan will provide the Company with promising business opportunities in the local real estate market. We will contribute great efforts in building a better community for the local residence,” stated Mr. Xiaojun Zhu.

Safe Harbor Statement

This press release contains forward-looking statements, which are subject to change. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All “forward-looking statements” relating to the business of China HGS Real Estate, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties which could cause actual results to differ. These factors include but are not limited to: the uncertain market for the Company’s business, macroeconomic, technological, regulatory, or other factors affecting the profitability of real estate business; and other risks related to the Company’s business and risks related to operating in China. Please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2013, as well as the Company’s Quarterly Reports on Form 10-Q that have been filed since the date of such annual report, for specific details on risk factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The Company’s actual results could differ materially from those contained in the forward-looking statements. The Company undertakes no obligation to revise or update its forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

About China HGS Real Estate, Inc.

China HGS Real Estate, Inc. (NASDAQ: HGSH), founded in 1995 and headquartered in Hanzhong City, Shaanxi Province, is a leading real estate developer in the region and holds the national grade I real estate qualification. The Company focuses on the development of high-rise, sub-high-rise residential buildings and multi-building apartment complexes in China’s Tier 3 and Tier 4 cities and counties with rapidly growing populations driven by increased urbanization. The Company provides affordable housing with popular and modern designs to meet the needs of multiple buyer groups. The Company’s development activity spans a range of services, including land acquisition, project planning, design management, construction management, sales and marketing, and property management. For further information about China HGS, please go to www.chinahgs.com.

Company contact:

Randy Xiong,
President of Capital Market
China Phone: (86) 091-62622612
Email: randy.xiong@chinahgs.com

Tuesday, August 19th, 2014 Uncategorized Comments Off on (HGSH) Signed its First Shanty Area Rebuilding Project Agreement

(VSTAD) Notice of Allowance Canadian Patent Further Expanding Stem Cell Platform

SOUTH SAN FRANCISCO, CA–(Aug 19, 2014) – VistaGen Therapeutics, Inc. (OTCQB: VSTAD), a biotechnology company applying pluripotent stem cell technology for drug rescue, drug discovery and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 2,487,058, entitled “Mesoderm and Definitive Endoderm Cell Populations.” This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will further expand VistaGen’s intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.

Together with the Company’s recently announced Notice of Allowance for related Canadian Patent Application 2,684,022, this most recent Canadian patent allowance strengthens VistaGen’s intellectual property relating to several key pluripotent stem cell research projects the Company is contemplating in Canada, including innovative projects involving liver safety, liver toxicity-based drug rescue, customized drug discovery assays for therapies to treat liver disease and diabetes, and exploratory nonclinical studies for potential regenerative medicine applications involving beta islet cells and other cells of the endoderm lineage.

About VistaGen Therapeutics

VistaGen is a stem cell company focused on drug rescue, drug discovery and regenerative medicine. We believe better cells lead to better medicines™ and that the key to making better cells is precisely controlling the differentiation of human pluripotent stem cells, which are the building blocks of all cells of the human body. For over 15 years, our stem cell research and development teams and collaborators have developed proprietary methods for controlling the differentiation of human pluripotent stem cells and the production and maturation of numerous specific types of adult human cells that we use, or plan to use, to reproduce complex human biology and disease and assess, in vitro, potential therapeutic benefits and safety risks of new drug candidates, including new chemical entities we are focused on producing through drug rescue. These are intended to be novel, proprietary and safer variants of once-promising small molecule drug candidates discovered, developed and optimized for efficacy by pharmaceutical and biotechnology companies, the U.S. National Institutes of Health, or academic laboratories, but discontinued prior to FDA approval due to unexpected heart or liver safety concerns.

Visit VistaGen at www.VistaGen.com, follow VistaGen at www.twitter.com/VistaGen or view VistaGen’s Facebook page at www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward-Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen’s drug and regenerative medicine research, discovery, development and rescue activities, its ability to enter into strategic licensing and partnering arrangements, risks and uncertainties relating to its protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the foregoing activities. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For more information:

Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-577-3613
Investor.Relations@VistaGen.com

Mission Investor Relations
IR Communications
Atlanta, Georgia
www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Tuesday, August 19th, 2014 Uncategorized Comments Off on (VSTAD) Notice of Allowance Canadian Patent Further Expanding Stem Cell Platform

(CLRB) to Host Conference Call on August 20th

MADISON, Wis., Aug. 18, 2014  — Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second quarter 2014 financial results and provide an update on each of its development programs on Wednesday, August 20th at 5:00 PM ET.

Event Details:

Interested investors may participate in the conference call by dialing 888-646-8293 (domestic) or 973-453-3065 (international). A replay will be available for one week following the call by dialing 855-859-2056 for domestic participants or 404-537-3406 for international participants and entering conference ID 90511388 when prompted. Participants may also access both the live and archived webcast of the conference call on the investor relations section of Cellectar’s web site, www.cellectar.com.

To Ask Questions:

Following prepared remarks and time permitting, management will provide an opportunity for participants dialed into to the live teleconference to ask questions. Investors may also e-mail their questions to ir@cellectar.com. E-mail questions will be accepted until 12:00 noon ET on Wednesday, August 20, 2014.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar’s compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to “find, treat and follow” malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. I-124-CLR1404 has been granted Orphan status as a diagnostic for the management of gliomas from the US FDA. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of 2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking.

CONTACT: INVESTOR CONTACT

         Kate McNeil
         Vice President of IR, PR & Corporate Communications
         Cellectar Biosciences, Inc.
         Phone: (347) 204-4226
         Email: kmcneil@cellectar.com
Monday, August 18th, 2014 Uncategorized Comments Off on (CLRB) to Host Conference Call on August 20th

(KNDI) First 208 EVs Delivered to Launch Shanghai Car-Share Program

JINHUA, China, Aug. 18, 2014  — Kandi Technologies Group, Inc. (the “Company” or “Kandi”) (Nasdaq:KNDI), today announced that the first 208 Kandi brand electric vehicles (“EV”) were delivered as the official launch of Shanghai Jinshan public pure EV sharing program (the Shanghai Jinshan “Car-Share” Program) and Long-term Group Leasing Program. On August 14, 2014, ZuoZhongYou (Shanghai) Electric Vehicle Service Co., Ltd. (“ZZY-Shanghai”), which was formally established on June 16, 2014 in Shanghai by Zhejiang ZuoZhongYou Electric Vehicle Service Co., Ltd. (the “Service Company” or “ZZY”) hosted a launching ceremony at Jinshan District in Shanghai. All of 208 EVs were sent to rental stations in Zhu Jing, Shi Hua, Feng Jing and Ting Lin, four towns at Jinshan for users’ immediate use.

As previously announced on April 14, 2014, Mr. Ma Jing the Deputy Director of Electric Vehicles Development from the Shanghai Municipal Commission of Economic and Information Technology and his delegation group visited Kandi Electric Vehicles (Shanghai) Co., Ltd. (“Kandi Shanghai”)’s production base and initiated Shanghai Public EV Sharing System Pilot Project. During the visit, Mr. Ma Jing laid out the targeted plan for the delivery of 3000-5000 Kandi Brand pure EVs by the end of 2014.

“The official launch of Shanghai Jinshan Car-Share Program has demonstrated the expansion of Hangzhou Car-Share Program into other major cities in China as the most preferred business model for EV development. We anticipate to see more and more cities adapting the Car-Share Program and Long-term Group Leasing Program in the near future,” Mr. HuXiaoming, Chairman and Chief Executive Officer of Kandi Technologies, commented.

About the Car-Share Program

Zhejiang ZuoZhongYou Electric Vehicle Service Co., Ltd. (“ZZY”) is the first in market to initiate the public pure EV sharing program (the “Car-Share” Program). Kandi Technologies, through its 50% ownership interest in Kandi Electric Vehicles Group Co., Ltd. (the “JV Company”), indirectly holds a 9.5% interest in ZZY.

Individually driven pure EVs are used in the Car-Share Program. The charging/parking stations which provide a variety of services, such as charging, maintenance, battery recycling, are located at airports, train stations, hotels, business centers, selected residential areas and other places that are typically congested. A network system provides EV rental service to individual drivers in and around the city. It also provides EV maintenance and battery charging to self-service users. Lastly, a tracking system allows the Car-Share Program management to keep a close watch at the status and precise location of each vehicle.

This Car-Share Program model has been implemented in Hangzhou since the second half of 2013, and has now begun to expand into other major cities in China.

The Group Long-term Lease Project is a lease model that uses enterprise, community or village as a lease unit and each unit leases a minimum of 100 EVs with a group lease term at a minimum of three years.

About Kandi Technologies Group, Inc.

Kandi Technologies Group, Inc. (Nasdaq:KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicles. Kandi has established itself as one of the world’s largest manufacturers of pure electric vehicle (EV) products, Go-Kart vehicles, and tricycle and utility vehicles (UTVs), among others. More information can be viewed at its corporate website is http://www.kandivehicle.com. Kandi routinely posts important information on its website.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACT: Kandi Technologies Group, Inc.

         Ms. Kewa Luo
         Phone: 1-212-551-3610
         Email: IR@kandigroup.com
Monday, August 18th, 2014 Uncategorized Comments Off on (KNDI) First 208 EVs Delivered to Launch Shanghai Car-Share Program

(CLDN) Closing of Public Offering of Common Stock

SAN DIEGO, Aug. 18, 2014  — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, resulting in gross proceeds from the offering of $43.7 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon.

Credit Suisse and Jefferies LLC acted as joint book-running managers for the offering and Stifel and Wedbush PacGrow Life Sciences acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 12, 2014. The offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC at Eleven Madison Avenue, Level 1B, New York, NY 10010, Attn: Prospectus Department, by calling toll free 1-800-221-1037, or by e-mail at newyork.prospectus@credit-suisse.com, or alternatively from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 1-877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

CONTACT: Fredrik Wiklund
         Vice President, Corporate Development and Investor Relations
         (858) 432-7215
         fwiklund@celladon.com

 

Monday, August 18th, 2014 Uncategorized Comments Off on (CLDN) Closing of Public Offering of Common Stock

(CTP) Leslie Cook Joins as a Principal in Consumer and Retail Practice

Insider Perspective and Knowledge of Specialty Retail Sector

CTPartners (NYSE MKT: CTP), a leading global retained executive search firm, today announced that Leslie Cook has recently joined the Global Consumer and Retail Practice as a Principal in New York.

With over 20 years’ experience in executive search, Leslie has focused exclusively on the consumer, retail and wholesale sectors. She has spearheaded executive searches spanning all aspects of management including merchandising, design, marketing, product development, sourcing/production, operations management, human resources, and planning and allocation.

Prior to joining CTPartners, Leslie led her own independent search consultancy, Leslie Cook Partners, LLC. Additionally, Leslie spent 17 years as a Senior Vice President with Kirk Palmer and Associates.

Leslie’s executive search work is further informed by her nine years in the retail industry at Jordan Marsh, Inc., where she held roles of increasing responsibility in sales management and merchandising. Her human resources experience there included assignments in executive recruitment, executive placement and career development, and finally, as the Director of Corporate Human Resources.

Tim Boerkoel, Global Head of the Consumer and Retail Practice said, “Leslie Cook is an accomplished executive search professional who is well known within the retail and consumer industry. She possesses rich experience and understanding of partnering closely with both clients and candidates and is a trusted advisor to many. We are thrilled to have Leslie be part of our growing Consumer and Retail Team and we value her as a true asset to our practice.”

About CTPartners

CTPartners is a leading global executive search firm that is designed to deliver in-depth expertise, creative strategies, and outstanding results to clients worldwide. Committed to a philosophy of partnering with its clients, CTPartners offers a proven track record in C-Suite, top executive, and board searches, as well as extensive experience in serving private equity and venture capital firms.

From its 30 offices in 18 countries, CTPartners serves clients with a global organization of more than 500 professionals and employees, offering expertise in board advisory services, key leadership functions, and executive recruiting services in the financial services, life sciences, industrial, professional services, retail and consumer, and technology, media and telecom industries.

For more information visit CTPartners (www.ctnet.com). Connect with CTPartners on LinkedIn, Twitter and Facebook to follow ongoing news developments and insights about the latest industry trends.

Monday, August 18th, 2014 Uncategorized Comments Off on (CTP) Leslie Cook Joins as a Principal in Consumer and Retail Practice

(DWA) Appoints Fazal Merchant As Chief Financial Officer

Current CFO Lew Coleman Shifts Focus to Global Growth in New Role as Vice Chairman

GLENDALE, Calif., Aug. 18, 2014  — Fazal Merchant is joining DreamWorks Animation as the company’s Chief Financial Officer.  Merchant joins DreamWorks following current CFO Lew Coleman’s shift earlier this month to the role of Vice Chairman, where he will focus on global growth initiatives.  Merchant will officially start on September 15, 2014.

“As we transition and augment our executive leadership team to best fit the needs of the company, I’m thrilled to welcome Fazal into the role of CFO,” said Lew Coleman, DreamWorks Animation Vice Chairman and Acting Chief Accounting Officer.  “He brings with him not only passion for our business, but also experience drawn from senior leadership roles across multiple industries, which will be an incredible asset as we continue to grow and diversify.”

Merchant comes to DreamWorks Animation from DIRECTV, where he was most recently SVP and CFO of DIRECTV Latin America; until April 2014, Merchant also held the title of SVP, Treasurer & Corporate Development.  Prior to joining DIRECTV in July 2012, Merchant was a managing director and group head at the Royal Bank of Scotland.   Prior to that, he was a managing director in the Investment Banking Division of Barclays Capital, where he spent seven years advising clients on strategy, financing, and risk solutions. Merchant also spent nine years at Ford Motor Company in various treasury and finance management positions across functions in the U.S. and Europe.

About DreamWorks Animation
DreamWorks Animation (Nasdaq: DWA) creates high-quality entertainment, including CG animated feature films, television specials and series and live entertainment properties, meant for audiences around the world. The Company has world-class creative talent, a strong and experienced management team and advanced filmmaking technology and techniques. DreamWorks Animation has been named one of the “100 Best Companies to Work For” by FORTUNE® Magazine for five consecutive years. In 2013, DreamWorks Animation ranked #12 on the list.  All of DreamWorks Animation’s feature films are produced in 3D. The Company has theatrically released a total of 29 animated feature films, including the franchise properties of Shrek, Madagascar, Kung Fu Panda, How to Train Your Dragon, Puss In Boots, and The Croods.

Monday, August 18th, 2014 Uncategorized Comments Off on (DWA) Appoints Fazal Merchant As Chief Financial Officer

(WPCS) Shareholder Approval for the Sale of Seattle Operations

Divestiture Will Provide Over $1.5 Million in Working Capital

EXTON, PA–(Aug 18, 2014) – WPCS International Incorporated (NASDAQ: WPCS) (the “Company”), which specializes in contracting services for communications infrastructure and the development of a digital currency trading platform, today announced that on August 15, 2014 the Company held a special meeting of stockholders at which a majority of the Company’s shareholders overwhelmingly approved the sale of substantially all of the assets of its wholly-owned subsidiary WPCS International — Seattle, Inc. (the “Seattle Operations”). Over 94% of the total shares voted by the majority of shareholders in this special meeting were in favor of this transaction.

The agreement proposes that EC Company, an Oregon-based electrical contracting company, will purchase substantially all of the assets and assume certain liabilities of the Seattle Operations, in an all-cash transaction, at a target sales price of approximately $2.7 million, subject to certain adjustments based upon the closing date balance sheet of the Seattle Operations. The Company expects that this transaction will close on or around August 31, 2014 and that it will generate over $1.5 million in working capital.

According to Sebastian Giordano, Interim CEO of WPCS, “On behalf of the Board of Directors and entire management team, we want to thank our shareholders for demonstrating their support, evidenced by their voting in favor of the sale of our Seattle Operations. This is yet another critical milestone in our overall restructuring plan, and it will provide the Company with, amongst other benefits, some much needed working capital.”

About WPCS International Incorporated
WPCS operates in two business segments: (1) providing communications infrastructure contracting services to the public services, healthcare, energy and corporate enterprise markets worldwide; and (2) developing a digital currency trading platform. For more information, please visit www.wpcs.com, www.btxtrader.com and www.gocelery.com.

Statements about the Company’s future expectations, including future revenue and earnings and all other statements in this press release, other than historical facts, are “forward looking” statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time. The Company’s actual results could differ materially from expected results. In reflecting subsequent events or circumstances, the Company undertakes no obligation to update forward-looking statements.

INVESTOR CONTACT:
Capital Markets Group, LLC
Valter Pinto
PH: (914) 669-0222 or (212) 398-3486
Email Contact

Monday, August 18th, 2014 Uncategorized Comments Off on (WPCS) Shareholder Approval for the Sale of Seattle Operations

(JRJC) Launches China’s First Integrated, Web-Based Securities Trading Service Platform

CITIC Securities Named as an Inaugural Partner

BEIJING, Aug. 18, 2014  — China Finance Online Co. Limited (“China Finance Online”, or the “Company”) (NASDAQ GS: JRJC), a leading web-based financial services company that provides Chinese retail investors online access to stocks, commodities and wealth management products, today announced that it has launched China’s first independent web-based securities trading platform, “Zhengquantong (“Securities Master”)”, on the leading financial portals it operates, www.jrj.com and www.stockstar.com. Securities Master is the product of a new strategic partnership China Finance Online has entered into with the largest brokerage firm in China, CITIC Securities Co., Ltd. (SHA: 600030) (“CITIC”), to seamlessly integrate China Finance Online’s state-of-the-art, web-based architecture with CITIC’s robust trading and settlement system.

Securities Master has been designed as a fully integrated securities-trading platform that will be easily accessible to investors through a highly-intuitive user interface via computers, smartphones, tablets, and smart TVs. By creating a simple and seamless experience for retail investors to access market information, open accounts and trade in real-time, investors will be able to manage their finances more effectively and efficiently via Securities Master. For the first time, active investors will have fast access to online securities trading with professional-level market data, analytics, research reports, as well as real-time online advisory services to facilitate trading decisions.

“We are extremely excited to form this groundbreaking partnership with CITIC, given China’s accelerating financial and investment reforms and the liberalization of financial instruments available to Chinese investors,” stated Mr. Zhiwei Zhao, Chairman and CEO of China Finance Online. “By bringing together leaders in both brokerage services and internet finance, we are creating a leading-edge integrated financial service ecosystem for Chinese investors. In addition to enhancing our online trading capabilities, we will also collaborate with our partners in wealth management, investment advisory and other value-added internet finance service offerings. Going forward, we will continue to leverage, expand and optimize our innovative and comprehensive financial platform for China’s growing population of retail investors, further strengthening our foundation for monetization.”

As China’s leading financial information center, the Company’s portals, jrj.com and stockstar.com, have aggregated a large user base of over tens of millions of monthly active users. By providing accurate, consistent and reliable financial information to Chinese investors for over a decade, the Company’s expertise and value proposition in internet finance have been widely recognized by major financial services providers like CITIC, as well as the wider investment community. Through this partnership with CITIC, the new web-based securities trading platform will enable both companies to quickly transfer their current user bases to online securities trading system as well as to expand and attract new users.

Conference Call Information

The Company will hold a conference call on Tuesday, August 19, 2014 at 7:30 am Eastern Time or 7:30 pm Beijing Time to discuss the web-based financial portals in more detail.

United States: +1-800-742-9301
International Dial-In: +61-283733610
China Domestic: 4001-203170
Hong Kong: +800-906648
Conference ID: #89855480

The replay will be accessible through August 26, 2014 by dialing the following numbers:

United States: +1-855-452-5696
International: +61-2-90034211
Conference ID: #89855480

About China Finance Online

China Finance Online Co. Limited is a leading web-based financial services company that provides Chinese retail investors access to stocks, commodities and wealth management products. The Company’s two prominent flagship portal sites, www.jrj.com and www.stockstar.com, are ranked as top financial websites in China. In addition to the web-based securities trading platform, the Company offers basic financial software, information services and securities investment advisory services to retail investors in China. Through its subsidiary, Shenzhen Genius Information Technology Co. Ltd., the Company provides financial database and analytics to institutional customers including domestic financial, research, academic and regulatory institutions. China Finance Online also provides brokerage services in Hong Kong.

About CITIC Securities Co., Ltd.

CITIC Securities Co., Ltd. is the largest securities firm in China by total assets and market share with 271.4 billion RMB in total assets. Underwriting a total of 213.8 billion RMB, CITIC ranked No. 2 in equity underwriting and No. 1 in fixed income underwriting in 2013. Managing over 504.9 billion RMB, CITIC also ranked No. 1 in asset management. CITIC is the parent company of CLSA Asia Pacific Markets. CITIC is CITIC Group’s securities arm and CITIC Group is one of China’s largest state-owned financial conglomerates.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, this release contains the following forward-looking statements regarding:

  • our prospect on the newly launched web-based securities trading platform, “Zhengquantong (“Securities Master”)”, and its integration with our existing financial services and CITIC’s trading and settlement system;
  • our prospect on the growth of our financial platform and online trading capabilities;
  • our prospect on transferring CITIC’s and our user bases to the newly launched securities trading platform as well as expanding and attracting new users;
  • our prospect on the collaboration with CITIC and our partners in wealth management, investment advisory and other value-added internet finance service offerings; and
  • the market prospect of the business of internet finance.

Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which risks and uncertainties include, among others, the following:

  • the changing customer needs, regulatory environment and market condition that we are subject to;
  • the uneven condition of the world and Chinese economy that could lead to volatility in the equity markets and affect our operating results in the coming quarters;​
  • the impact of the changing conditions of the Chinese stock market, Hong Kong stock market and global financial market on our future performance;
  • the unpredictability of our strategic transformation and growth of new businesses, including our online securities trading services and platform;
  • the degree to which our strategic collaborations with partners will yield successful outcome;
  • the prospect of integrating Yinglibao with our newly launched web-based securities trading platform;
  • the prospect for China’s high-net-worth and middle-class households;
  • the prospect of equipping our customer specialists with new technology, tools and financial knowledge;
  • the competition we are facing in the new business of internet finance and online securities trading;
  • wavering investor confidence that could impact our business; and​
  • possible non-cash goodwill, intangible assets and investment impairment may adversely affect our net income.​

Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F under “Forward-Looking Information” and “Risk Factors”. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Monday, August 18th, 2014 Uncategorized Comments Off on (JRJC) Launches China’s First Integrated, Web-Based Securities Trading Service Platform

(NEO) Announces Pricing of $32.2 Million Public Offering

Seven Million Share Offering at $4.60 per Share

FT. MYERS, Fla., Aug. 15, 2014  — NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share.  The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million.  The net proceeds to the Company, after deducting the underwriters’ discounts and other estimated offering expenses, will be approximately $30.0 million.  The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt.  NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover over-allotments, if any.

William Blair & Company, L.L.C. is the sole book-running manager and Craig-Hallum Capital Group LLC is co-lead manager for the offering.  Stephens Inc., Roth Capital Partners, LLC, Sidoti & Company, LLC and Dawson James Securities, Inc. are serving as co-managers for the offering.

This offering is being conducted pursuant to a shelf registration statement that was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on January 3, 2014.  The offering is being made only by means of a prospectus supplement and accompanying prospectus, forming an effective part of the registration statement.  A preliminary prospectus supplement and the accompanying prospectus relating to these securities have been filed with the SEC and are available at the SEC’s website at www.sec.gov.  Before investing, you should read the prospectus supplement and the accompanying prospectus for information about NeoGenomics and this offering.  Copies of the preliminary prospectus supplement, the final prospectus supplement (when available) and accompanying prospectus relating to these securities may also be obtained from William Blair & Company, L.L.C., Attention Prospectus Department, 222 West Adams Street, Chicago, Illinois 60606, by telephone at (800)-621-0687, or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry.  The Company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, Fresno and West Sacramento CA, Tampa and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements.  Actual results could differ materially from such statements expressed or implied herein.  Factors that might cause such a difference include, among others, the Company’s ability to continue gaining new customers, offer new types of tests and otherwise implement its business plan.  As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC.

Friday, August 15th, 2014 Uncategorized Comments Off on (NEO) Announces Pricing of $32.2 Million Public Offering

(SYRG) Provides Production and Operations Update

PLATTEVILLE, CO–(August 15, 2014) – Synergy Resources Corporation (NYSE MKT: SYRG), a U.S. oil and gas exploration and production company focused in the Denver-Julesburg Basin, provides an update of its production and operations in the Wattenberg Field. Production rates for Synergy’s recent horizontal wells follow*:

Name of Pad Number of wells Average # of fracs per well Days of Production Average Daily (BOED)
Production
per well 8/8ths
% Oil
Cut
Cost Per
Well $MM
Renfroe 5 18 270 219 66% $3.6
Leffler 6 20 180 145 65% $3.7
Phelps 5 26 90 430 69% $4.0
Union 6 20 30 566 74% $3.9

*For further production history details please refer to the corporate presentation at www.syrginfo.com

Also, the five wells on the Renfroe pad have paid back approximately 90% of all costs during the first eleven months of production.

Beginning with the Union pad, Synergy began drilling well bores 220 feet apart which is a more densely spaced drilling pattern and allows for up to 24 wells per 640 acres. This tighter spacing provides Synergy with a potential inventory of over 1,000 wells on its 27,386 net acres in the Wattenberg.

Horizontal drilling operations and completions are progressing according to plan. The four Kelly Farms wells are now in early production. The six Eberle wells, which include two mid reach 7,000 foot extended lateral wells with 45-47 frac stages each, are in the final completion stage and are flowing back or in initial production.

Synergy’s Wattenberg Field development continues with Rig #131 drilling the third well on the Kiehn pad where the company plans on a total of eight wells comprised of 4 Codell and 4 Niobrara C bench wells. Rig #134 is drilling the third well on the Weld 152 pad where the company plans on drilling six wells comprised of 3 Codell, 2 Niobrara B bench and 1 Niobrara C bench well. The third rig in Synergy’s operated program, Rig #138, is scheduled to move to the Wiedeman pad later this month and begin drilling eight wells in September. The Wiedeman pad will consist of 4 Codell and 4 Niobrara wells. Four of the Wiedeman wells are planned to be 9,000 foot extended reach lateral wells and the other four will be standard length lateral wells of 4,000 feet.

Depending on contribution from its non-operated horizontal wells and the performance of the Kelly Farms and Eberle wells, Synergy believes production for its fiscal fourth quarter ending August 31, 2014 will range between 5,800-6,200 BOED. With this new flush production coming on line from the Kelly Farms and Eberle pads, Synergy believes it will exit its fiscal year end at a production rate of between 8,000-9,500 BOED.

In the Northeast Wattenberg Extension Area (Extension Area) Synergy has reviewed the lab results from the core data taken from the vertical Buffalo Run test well and is currently preparing to permit 12 wells in the Extension Area. Once these permits are approved, Synergy plans on drilling a horizontal well targeting the Greenhorn formation. Depending on the results of the initial horizontal well, the company will move forward with multi-well pad drilling on its 25,765 net acres in this area.

Craig Rasmuson, Chief Operating Officer, of Synergy commented, “We are making tremendous strides in the development of our assets in the Wattenberg Field. In spite of continued challenges from mid-stream processing constraints, we are achieving record growth for the company in production and cash flow. The 30 day results from our most recent wells on the Union pad are the best we have achieved so far. We are doing so while maintaining a keen eye on controlling costs and developing our leases in a responsible manner. We are very pleased with the production rates from our horizontal pads and the high percentage of oil in the production mix, which is generating an attractive realized price per BOE for the company. We look forward to realizing further efficiencies on our mid and extended reach lateral wells in fiscal 2015. We continue to expand our foot print through organic leasing efforts and asset purchases. We are further accelerating our development with the addition of a third horizontal rig, Rig #138 which is moving to the Wiedeman pad, and by adding new permits. In addition to the aforementioned wells and pads, Synergy has 66 permits approved and another 120 permits in process for horizontal wells in the Wattenberg Field. In the Extension Area we are very excited about the prospects in the Greenhorn formation on our leasehold and the recent results from industry competitors in the Niobrara and Codell formations in the area. We look forward to keeping the market and our shareholders apprised of our progress.”

Synergy is presenting at Enercom’s The Oil & Gas Conference 19 ® 2014 at the Westin Hotel in Denver on Monday, August 18th at 11:20am. Interested parties may view the slide presentation and a link to the live audio webcast by going to Synergy’s website at http://www.syrginfo.com and clicking on the webcast link under the Investor Relations section of the website.

The live webcast will also be available on The Oil & Gas Conference 19 ® website at http://www.theoilandgasconference.com.

About Synergy Resources Corporation

Synergy Resources Corporation is a domestic oil and natural gas exploration and production company. Synergy’s core area of operations is in the Denver-Julesburg Basin, which encompasses Colorado, Wyoming, Kansas, and Nebraska. The Wattenberg field in the D-J Basin ranks as one of the most productive fields in the U.S. The company’s corporate offices are located in Platteville, Colorado. More company news and information about Synergy Resources is available at www.syrginfo.com.

Important Cautions Regarding Forward Looking Statements

This press release may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates”, “should”, “likely” or similar expressions, indicates a forward-looking statement. These statements are subject to risk and uncertainties and are based on the beliefs and assumptions of management, and information currently available to management. The actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. Certain material factors or assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information. The identification in this press release of factors that may affect the company’s future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Factors that could cause the company’s actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: the success of the company’s exploration and development efforts; the price of oil and gas; worldwide economic situation; change in interest rates or inflation; willingness and ability of third parties to honor their contractual commitments; the company’s ability to raise additional capital, as it may be affected by current conditions in the stock market and competition in the oil and gas industry for risk capital; the company’s capital costs, which may be affected by delays or cost overruns; costs of production; environmental and other regulations, as the same presently exist or may later be amended; the company’s ability to identify, finance and integrate any future acquisitions; and the volatility of the company’s stock price.

Investor Relations Contact:
Jon Kruljac
Synergy Resources Corporation
jkruljac@syrginfo.com
Tel (303) 840-8166

Company Contact:
Rhonda Sandquist
Synergy Resources Corporation
rsandquist@syrginfo.com
Tel (970) 737-1073

Friday, August 15th, 2014 Uncategorized Comments Off on (SYRG) Provides Production and Operations Update
Top Small Cap Market News